Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06116890 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Primary completion date changed from estimate of Aug 31, 2026 to Jun 3, 2026
    • Enrollment target: estimated 180 to confirmed 170
    • Study completion date changed from estimate of Sep 30, 2026 to Jul 1, 2026
    • Eligibility criteria expanded, about 22 words
    • Site details revised at 2 of 84 sites
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 84 of 84 sites
    v20
  3. Primary completion date: Nov 2025 to Aug 31, 2026
    • Study completion date: Dec 2025 to Sep 30, 2026
    • Site details revised at 1 of 84 sites
    v19
  4. Site contacts updated at 1 of 84 sitesv18
  5. Eligibility criteria expanded, about 33 words
    • Site details revised at 8 of 84 sites
    v17
Show 15 earlier versionsHide 15 earlier versions
  1. Site details revised at 6 of 84 sitesv16
  2. Lead sponsor: Kyowa Kirin, Inc. to Kyowa Kirin Co., Ltd.
    • Site details revised at 3 of 84 sites
    v15
  3. Site details revised at 1 of 84 sitesv14
  4. Site details revised at 4 of 84 sitesv13
  5. Eligibility criteria expanded, about 48 words
    • Site details revised at 8 of 84 sites
    v12
  6. Site details revised at 5 of 84 sitesv11
  7. Site details revised at 7 of 84 sitesv10
  8. Study sites: 83 to 84v9
  9. Study sites: 82 to 83v8
  10. Site details revised at 1 of 82 sitesv7
  11. Study sites: 81 to 82v6
  12. Re-verified, no change to tracked fieldsv5
  13. Site details revised at 20 of 81 sitesv4
  14. Study sites: 80 to 81
    • Study title shortened, about 2 words
    v3
  15. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 28 to 80
    • Start date changed from estimate of Nov 2023 to Jan 31, 2024
    • Study title shortened, about 1 word
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
Trial Details
NCT Number NCT06116890
Lead Sponsor Kyowa Kirin Co., Ltd.
Conditions
(from sponsor)		 Neovascular Age-Related Macular Degeneration (nAMD)
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov